This is a newsletter from the JDRF. I am including the contents.- Happy Tuesday!
- In a newly published study in the New England Journal of Medicine, semaglutide (brand names Ozempic®, Rybelsus®, and Wegovy®) improved blood-sugar control and decreased mealtime and basal insulin requirements in ten newly diagnosed individuals.
- Lonza and Vertex broke ground on a manufacturing facility in New Hampshire that will support the development and commercialization of Vertex’s T1D cell therapies portfolio. JDRF CEO Aaron Kowalski was in attendance along with U.S. Senator and Senate Diabetes Caucus Co-Chair Jeanne Shaheen.
- Injections, whether insulin or other medications such as Ozempic and Wegovy, can be painful and uncomfortable. Check out some tips to make them go more smoothly.
- JDRF has partnered with Antidote and Beyond Type 1 to launch the first-ever Spanish language clinical trial search tool for people living with type 1 diabetes (T1D). This tool will make it easier for Spanish-speaking members of the T1D community to find and enroll in clinical trials, and help drive research progress forward. Learn more.
- JDRF se ha asociado con Antidote y Beyond Type 1 para lanzar la primera herramienta de búsqueda de ensayos clínicos en español para personas que viven con diabetes tipo 1 (DT1). Esta herramienta facilitará a los miembros hispanohablantes de la Comunidad de diabetes tipo 1 a encontrar ensayos clínicos e inscribirse en ellos, y ayudar a impulsar el progreso de la investigación. Obtenga más información aquí.
- Roche announced that it received clearance for the Accu-Chek Solo® micropump system. The micropump is cleared as an alternate controller enabled (ACE) pump meaning that it could be integrated into an automated insulin delivery (AID) system in the future.
- Novo Nordisk **launched MyInsulinRx**™, a cash offer program in which eligible patients with a prescription can get a 30-day supply (up to three vials or two packs of FlexPen®/FlexTouch®/PenFill® pens) of any combination of current Novo Nordisk insulins for $35.
- Abbott is acquiring Bigfoot Biomedical, maker of Bigfoot Unity, an insulin management system. Bigfoot is led by former JDRF CEO Jeffrey Brewer, and the JDRF T1D Fund invested in Bigfoot.
- Sidra Medicine (a member of Qatar Foundation) has been awarded a grant from JDRF to support the establishment of a program in Qatar that combines autoantibody and genetic screening for children with T1D.